P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
Naeem Khan,Robert Kerrin Hills,Paul Virgo,S Couzens,N Clark,Amanda F. Gilkes,Paul G. Richardson,Steven Knapper,David Grimwade,Nigel H. Russell,Alan Kenneth Burnett,Sylvie D. Freeman +11 more
TL;DR: CD33 expression is a predictive factor for GO effect in adult AML; although GO does not appear to benefit the non-CBF AML patients with lowest CD33 expression a higher GO dose may be more effective for CD33-low but notCD33-high younger adults.
Journal ArticleDOI
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.
Dharminder Chauhan,Madhavi Bandi,Ajita V. Singh,Arghya Ray,Noopur Raje,Paul G. Richardson,Kenneth C. Anderson +6 more
TL;DR: The preclinical studies provide the rationale for novel therapeutics targeting SIRT1 in MM and enhance the cytotoxic activity of bortezomib or dexamethasone.
Journal ArticleDOI
Genetic variation associated with bortezomib-induced peripheral neuropathy
Reyna Favis,Yu Sun,Helgi van de Velde,Erin Broderick,Laura Levey,Michael Meyers,George Mulligan,Jean-Luc Harousseau,Paul G. Richardson,Deborah Ricci +9 more
TL;DR: Genes associated with immune function, CTSS, reflexive coupling within Schwann cells (GJE1, drug binding), drug binding, and neuron function (TCF4, DYNC1I1) are associated with bortezomib-induced PN in this study.
Journal ArticleDOI
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial
Aurore Perrot,Valérie Lauwers-Cances,Titouan Cazaubiel,Thierry Facon,Denis Caillot,Lauriane Clement-Filliatre,Margaret Macro,Olivier Decaux,Karim Belhadj,Mohamad Mohty,Lionel Karlin,Jean Claude Eisenmann,Mourad Tiab,Frederique Orsini,Cyrille Touzeau,Xavier Leleu,Hervé Avet-Loiseau,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson,Philippe Moreau,Michel Attal +21 more
TL;DR: The combination of lenalidomide, bortezomib and dexamethasone with transplant was associated with significantly longer progression-free survival (PFS) (primary endpoint) compared to RVd alone and overall survival at 4 years was similar in both groups.
Journal ArticleDOI
Current strategies for treatment of relapsed/ refractory multiple myeloma
Jacob P. Laubach,Peter M. Voorhees,Hani Hassoun,Andrzej Jakubowiak,Sagar Lonial,Paul G. Richardson +5 more
TL;DR: The immunomodulatory agents and proteasome inhibitors represent the cornerstone of treatment in this setting, with combination regimens incorporating these drugs demonstrating encouraging rates and duration of response, including the newer agents, pomalidomide and carfilzomib.